Highlights
In this retrospective single-center analysis of 128 adults with myelodysplastic neoplasms undergoing allogeneic hematopoietic cell transplantation, pretransplant therapy did not translate into better post-transplant outcomes.
Although IPSS-M improved before transplantation in a subset of patients, molecular or composite-risk “downstaging” was modest and showed no clear survival advantage.
